Viatris Pharmaceuticals Co

Company snapshot

Viatris Healthcare is a pharma organization headquartered in FR. Primary therapeutic focus areas include Moderate to severe systemic lupus erythematosus, Lupus Erythematosus, Systemic, Acute Myocardial Infarction, Stable Coronary Artery Disease, Not applicable - healthy volunteer trial. NovaPharmaNews links 8 clinical program(s), 17 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (6), phase 2 (1), phase 1 (1).

• 9 approved product(s) across US/EU regulatory metadata.
• 8 active pipeline program(s) linked via ClinicalTrials.gov.
• 8 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Viatris Pharmaceuticals Co. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Viatris Pharmaceuticals Co.

1. Jun 8, 2026 Clinical update

   ID-076A301 — Phase 3

2. Jun 8, 2026 Clinical update

   ID-064-108 — Phase 1

3. Jun 8, 2026 Clinical update

   Cenerimod — Phase 3

4. Jun 8, 2026 Clinical update

   Cenerimod 4 mg — Phase 3

5. Jun 8, 2026 Clinical update

   Cenerimod 4 mg, Cenerimod matching placebo — Phase 3

View all clinical trial activity →

• What is Viatris Pharmaceuticals Co?

  Viatris Healthcare is a pharma organization headquartered in FR. Primary therapeutic focus areas include Moderate to severe systemic lupus erythematosus, Lupus Erythematosus, Systemic, Acute Myocardial Infarction, Stable Coronary Artery Disease, Not applicable - healthy volunteer

• Is Viatris Pharmaceuticals Co publicly traded?

  Viatris Pharmaceuticals Co appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Viatris Pharmaceuticals Co develop or market?

  We link 23 drug profile(s) where Viatris Pharmaceuticals Co is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/viatris-healthcare-limited#company-drugs.

• What are the latest developments for Viatris Pharmaceuticals Co?

  In the last 12 months our linked public records show 8 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Viatris Pharmaceuticals Co focus on?

  Viatris Pharmaceuticals Co focuses on Moderate to severe systemic lupus erythematosus, Lupus Erythematosus, Systemic, Acute Myocardial Infarction based on our analysis of their pipeline programs and drug development activities.